Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Kittichai Promrat, David E. Kleiner, Heather M. Niemeier, Elizabeth Jackvony, Marie Kearns, Jack R. Wands, Joseph L. Fava, Rena R. Wing – 23 December 2009 – Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity. Currently, there is no approved therapy for NASH. Weight reduction is typically recommended, but efficacy data are lacking.